Benzinga | Feb 9, 2021 07:04AM EST

Eloxx Highlights Publication Of Scientific Manuscript On ELX-02 In The Journal Of Cystic Fibrosis

WALTHAM, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ:ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that a scientific manuscript titled: "Targeting G542X CFTR Nonsense Alleles With ELX-02 Restores CFTR Function in Human-Derived Intestinal Organoids" was published in the Journal of Cystic Fibrosis.